Science Journal

 

 

Cancer Biology

 

ISSN: 2150-1041 (print); ISSN: 2150-105X (online), doi prefix:10.7537, Quarterly

 
Volume 6 / Issue 4, Cumulated No. 24, 25, 2016
Cover (jpg), Cover (pdf), Introduction, Contents

 

You can use the message in end of the article abstract to cite it.

To get Microsoft Documents: After you open the "Full Text" for each article, change the last 3 characters of the web address from .pdf to .doc (or .docx)

Welcome to send your manuscript to: sciencepub@gmail.com

When you submit manuscript(s), please mention that it is submitted to the Cancer Biology.

Marsland Press, PO Box 180432, Richmond Hill, New York 11418, USA, 347-321-7172

http://www.cancerbio.net

  

CONTENTS  

No.

Titles / Authors /Abstracts

Full Text

No.

1

Prognostic and predictive value of excision repair cross-complementation group-1protein expression in locally advanced bladder cancer

 

Wael Mansour1, Walid Almorsy1 and Maha shamloula2

 

Clinical Oncology Department, Histopathology Department Faculty of Medicine, Tanta University, Gharbia, Egypt.

walidaa1@hotmail.com

 

Abstract: Background: A viable treatment option for locally advanced bladder cancer includes tri-modality therapy with a combination of transurethral resection of bladder tumor (TURBT), chemotherapy and radiation therapy. Cisplatin is the most important chemotherapeutic agent for locally advanced bladder cancer and is usually administered with Gemcitabine. Increased expression of excision repair cross-complementation group 1 (ERCC1) protein is associated with resistance to cisplatin-based chemotherapy in various tumor types. The aim of the present study was to assess the prognostic and predictive value of (ERCC1) protein in locally advanced bladder cancer patients who received cisplatin-based chemotherapy. Patients and Methods: Seventy eight patients with non-metastatic locally advanced bladder cancer were included in this study between June 2013 and December 2014. Paraffin blocks obtained from all patients were analyzed for ERCC1 in immunohistochemical expression. Results: Complete response rate was higher in patients with negative ERCC1 expression (94.1%) than weak, moderate and strong positive (70%, 50%& 33.3% respectively) which was statistically significant (P= 0.019). The 2-year disease-free survival rates for patients with ERCC1-weak positive was 40%, while it was 16.7% in moderate +ve ERCC1-, and 0% in strong +ve ERCC1, however, it was 70% in ERCC1-negative patients. The interaction term between ERCC1 expression and adjuvant platinol based chemotherapy showed significance for overall survival (P = 0.001) and disease-free survival (P = 0.01). Conclusion: ERCC1appear to be potentially useful prognostic and predictive markers in non-metastatic locally advanced bladder cancer.

[Wael Mansour, Walid Almorsy and Maha shamloula. Prognostic and predictive Valueofexcision repair cross-complementation group-1protein expression in locally advanced bladder cancer. Cancer Biology 2016;6(4):1-8]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 1. doi:10.7537/marscbj060416.01.

 

Key words: locally advanced bladder cancer, ERCC1, cisplatin-based chemotherapy, prognosis.

Full Text

1

2

Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer

 

Loaie El-Helw 1,2, Abeda Raiyan1, Rajanee Bhana1

 

1 The Cancer Centre, the Royal Stoke University Hospital, Stoke-on-Trent, UK

2 The Department of Internal Medicine, the Medical Oncology Unit,

Mansoura University, Mansoura, Egypt

loaieelhelw@hotmail.com, loaie.elhelw@uhns.nhs.uk

 

Abstract: Neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) after 3 NAC cycles is an acceptable approach to achieve optimal cytoreduction in patients with advanced epithelial ovarian cancer (AEOC) who are not candidate for primary debulking surgery (PDS). The best timing of cytoreductive surgery and the role of late debulking surgery (LDS) after 6 cycles of NAC are still unclear. We aimed to study the outcome of such patients who were treated in our centre in the Royal Stoke University Hospital, Stoke-On-Trent between July 2009 and July 2014. One hundred and eight patients with AEOC were treated under our gynaecology oncology team during that period. Sixty six patients (61.1%) were in stages III and 42 (38.9%) in stage IV. All patients received NAC; 64 patients (59.3%) had paclitaxel and carboplatin regimen and 44 (40.7%) single agent carboplatin. Response to chemotherapy was assessed after 2 cycles; 81 patients (75%) had partial response, 21 (19.4%) stable disease and 6 (5.6%) progressive disease. Forty one patients (38%) proceeded to IDS after cycle 3 and 11 patients (10.2%) to LDS after cycle 6 but 56 (51.9%) had no debulking surgery (NDS). After a median follow up period of 18 months (range 6-84 months), 95 patients (88%) had relapsing/progressive disease. The median PFS durations were 13 and 12 months for patients who had either IDS and LDS respectively compared to 8 months for NDS. The 2 years PFS probabilities were 18% for patients who had IDS, 15% for LDS compared to 0% for NDS (P 0.000 Log rank test). The median overall survival (OS) durations were 48, 33 and 18 months for patients who had IDS, LDS and NDS respectively. The 2 years OS probabilities were 75% for patients who had either IDS, or LDS compared to 38% for NDS (P.000 Log rank test). In our study, we documented PFS and OS advantages for patients who IDS or LDS compared to NDS and therefore should be considered whenever possible as part of the primary treatment of AEOC patients. Interval debulking surgery (IDS) offers longer duration and higher probabilities of PFS and OS compared to LDS. More patients-therefore- should be selected for IDS. There is a need for improving NAC possibly with integrating target agents and the use of more intensified schedules.

[Loaie El-Helw, Abeda Raiyan, Rajanee Bhana. Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer. Cancer Biology 2016;6(4):9-15]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 2. doi:10.7537/marscbj060416.02.

 

Key words: advanced ovarian cancer-neoadjuvant chemotherapy-surgical debulking.

Full Text

2

3

Demographic and genetic study for a sample of Iraqi smokers

 

Bushra jasim Mohammed 1, Amina N. AL-Thwani 1, Raghuraman Kannan 2

 

1. Institute of genetic engineering and biotechnology, University of Baghdad, Iraq

2. University of Missouri/Colombia, USA

bbushra880@gmail.com

 

Abstract: Abstract: To examine the relationship between smoking and genetic and demographic aspects, using statistical analysis and genetic techniques. Subjects and methods: One hundred and fifty of apparently healthy Iraqi heavy smoker volunteers in comparison with fifty of apparently healthy non-smoker volunteers as a control group. Information for demographic study was taken from smokers and non smokers subjects according to a questionnaire that included, name, gender, age, consumption of pack number per day and duration of smoking, in the period from the beginnings of March 2014 to the end of June 2016. Through the molecular study, DNA was extracted by using the genomic isolation kit, then subjected to PCR analysis by using four sets of primers, then the PCR product were sequenced to detect the TP53 mutations. Results: The results of the demographic study revealed that the highest number of smokers located in the age group (36-45) represented 38 (25.33%) of the total number with significant difference (P≤ 0.05). The males constituted 91(60.67%) more than females 59 (39.33%) with the high significant (P≤ 0.01). The distribution of smokers according to pack consumption number by smokers a day showed that the highest number 134 (89.33%) consumed more than one pack per day against 16 (10.67%) of one pack a day with a high significant (P≤ 0.01). Moreover the highest number 46 (30.67%) had been smoking for (16-20) year, while the lowest number 22 (14.67%) of smokers had been smoking for (5-10) years with a high significant (P≤ 0.01). The results of genetic study showed the presence of many variations in different locations in TP53 gene such as G to C polymorphism which were found in exon 5 with the percentage of (47.3 %) among smokers in comparison with non smokers control (0.0%). On the other hand, it was observed that exon 6 had deletion in a high frequency among smoker individuals at a percentage of (19.3%) rather than in the non-smokers (0.0%); however, no genetic variations were shown in exons 7 and 8.

[Mohammed B, AL-Thwani A, Kannan R. Demographic and genetic study for a sample of Iraqi smokers.. Cancer Biology 2016;6(4):16-27]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 3. doi:10.7537/marscbj060416.03.

 

Keywords: demographic; genetic; Iraqi smokers

Full Text

3

4

Post-renal transplantation lymphoproliferative disorders: a retrospective review of two cases

 

Najla Moqadum, SamiaSobki, Najla Besharah, Amira Shaker

 

Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. Najlatm2011@hotmail.com

 

Abstract: Background: Post-transplant lymphoproliferative disorders (PTLD) encompass a heterogeneous spectrum of conditions ranging from reactive plasmacytic hyperplasia to malignant lymphoma. Many PTLD cases are a result of infection with Epstein–Barr virus (EBV). EBV is frequently detected in PTLD cells, and PTLD risk is highest among children and recipients who are EBV seronegative at the time of transplantation. PTLD is identified by having a high index of suspicion in the appropriate clinical setting. The diagnosis is made by histopathological evidence of lymphoproliferation, commonly with the presence of EBV DNA, RNA, or protein detected in tissue. Diagnosis of PTLD is not always straightforward. Despite of improvements with new tolerable therapies, survival of PTLD patients remains inferior, necessitating further international cooperation to improving long-term outcome of PTLD patients. We report here 2 cases of monomorphic B-cell PTLD (multiple myeloma and burkitt lymphoma) after successful renal transplantation. We compare clinicopathological features of these 2 cases with few cases reported in literature.

[Najla Moqadum, Samia Sobki, Najla Besharah, Amira Shaker. Post-renal transplantation lymphoproliferative disorders: a retrospective review of two cases. Cancer Biology 2016;6(4):28-31]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 4. doi:10.7537/marscbj060416.04.

 

Keywords: Renal transplant, PTLD, Multiple myeloma, Burkitt lymphoma

Full Text

4

5

Induction Chemotherapy With Capecitabine And Oxaliplatin (CAPOX) Followed By Concomitant Chemoradiotherapy Before Surgical Resection In Patients With Locally Advanced Rectal Cancer

 

Mohamed El-Shebiney M.D. and Alaa Maria M.D.

 

Clinical Oncology Department, Faculty of Medicine, Tanta University Hospital, Egypt.

alaamaria1@hotmail.com

 

Abstract: Background: Concomitant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is standard treatment for locally advanced rectal cancer. Induction chemotherapy has the advantage of earlier administration of systemic therapy and may improve distant control. Purpose: The purpose of the current study was to assess the efficacy and toxicity of induction chemotherapy (CAPOX) followed by concomitant CRT before surgery in patients with locally advanced rectal cancer. Patients and Methods: A total of 31 patients with locally advanced rectal cancer were randomly assigned to induction CAPOX followed by concomitant capecitabine-RT and surgery, then the patients were received an additional 4 cycles adjuvant capecitabine. The primary end point was assessment of pathological complete response (pCR) and the feasibility of surgical resection with sphincter preservation. Results: All patients underwent surgery with sphincter preservation procedure represented in 64.5% of patients. Complete resection (R0) was recorded in 93.5%, T downstaging in 61.3% and N downstaging in 51.6%. Pathological complete response was recorded in 19.4%. Two-year OS and DFS rates were 83% and 67.4%, respectively. Diarrhea was the most common grade 3/4 toxicity seen during the induction and concomitant CRT phases. Conclusions: Our results demonstrated that, induction CAPOX followed by capecitabine-RT is feasible with tolerable toxicity and results in encouragingly high rates of pCR, R0 resection, sphincter preservation and tumor downstaging in patients with locally advanced rectal cancer. Additional studies of this approach to examine more optimal regimens are warranted.

[Mohamed El-Shebiney and Alaa Maria. Induction Chemotherapy With Capecitabine And Oxaliplatin (CAPOX) Followed By Concomitant Chemoradiotherapy Before Surgical Resection In Patients With Locally Advanced Rectal Cancer. Cancer Biology 2016;6(4):32-40]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 5. doi:10.7537/marscbj060416.05.

 

KeyWords: Rectal cancer, induction chemotherapy, combined chemoradiotherapy, sphincter preservation

Full Text

5

6

Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer: Our Experience.

 

Loaie El-Helw1,2, Abeda Raiyan2, Hanaa Elkhenini3,4, Rajanee Bhana2

 

1The department of medical oncology, Mansoura University, Egypt, 2 The Royal Stoke Hospital, Stoke-on-Trent, UK, 3The department of public health, Mansoura University, Egypt, 4The department of E-Health, the University of Manchester, UK

loaieelhelw@hotmail.com, loaie.elhelw@uhns.nhs.uk

 

Abstract: Purpose: Neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) after 3 NAC cycles is an acceptable approach to achieve optimal cytoreduction in patients with advanced epithelial ovarian cancer (AEOC) who are not candidate for primary debulking surgery (PDS). The best timing of cytoreductive surgery and the role of late debulking surgery (LDS) after 6 cycles of NAC are still unclear. We aimed to study the outcome of such patients who were treated in our centre during the last 5 years. Methods: This was a retrospective study of AEOC patients who had NAC with or without IDS/LDS in the Royal Stoke Hospital, Stoke-On-Trent between July 2009 and July 2014. Results: One hundred and eight patients with AEOC were treated under our oncology team during that period. Sixty six patients (61.1%) were in stages III and 42 (38.9%) in stage IV. All patients received NAC; 64 patients (59.3%) had paclitaxel and carboplatin regimen and 44 (40.7%) single agent carboplatin. Response to chemotherapy was assessed after 2 cycles; 81 patients (75%) had partial response, 21 (19.4%) stable disease and 6 (5.6%) progressive disease. Forty one patients (38%) proceeded to IDS after cycle 3 and 11 patients (10.2%) to LDS after cycle 6 but 56 (51.9%) had no debulking surgery (NDS). After a median follow up period of 18 months (6-84 months), 95 patients (88%) had relapsing/progressive disease. The median PFS durations were 13 and 12 months for patients who had either IDS and LDS respectively compared to 8 months for NDS. The 2 years PFS probabilities were 18% for patients who had IDS, 15% for LDS compared to 0% for NDS (P 0.000 Log rank test). The median overall survival (OS) durations were 48, 33 and 18 months for patients who had IDS, LDS and NDS respectively. The 2 years OS probabilities were 75% for patients who had either IDS, or LDS compared to 38% for NDS (P.000 Log rank test). Conclusion: In our study, we documented PFS and OS advantages for patients who IDS or LDS compared to NDS and therefore should be considered whenever possible as part of the primary treatment of AEOC patients. Interval debulking surgery (IDS) offers longer duration and higher probabilities of PFS and OS compared to LDS. More patients-therefore- should be selected for IDS. There is a need for improving NAC possibly with integrating target agents and the use of more intensified schedules. ICON8B trial is currently addressing that.

[Loaie El-Helw, Abeda Raiyan, Hanaa Elkhenini, Rajanee Bhana. Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer: Our Experience. Cancer Biology 2016;6(4):41-47]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 6. doi:10.7537/marscbj060416.06.

 

Key words: advanced ovarian cancer-neoadjuvant chemotherapy-surgical debulking

Full Text

6

7

IL-33/ST2 Axis and Prohibitin in Breast Cancer: Clinicopathological and Prognostic Significance

 

Amina El-Sayed1, Amany A. Ghazy2, Rabie R. Abdelwahed3, Eman M. Saied4

 

1 Department of Immunology and Allergy, Medical Research Institute, Alexandria University.

2 Department of Microbiology and Immunology, Faculty of Medicine, Kafrelskeikh University.

3 Department of Surgery, Medical Research Institute, Alexandria University.

4 Department of Pathology, Faculty of Medicine, Kafrelsheikh University.

dremansaied@gmail.com

 

Abstract: Background: Breast cancer (BC) is an important health challenge that women face and affects their safety and productivity. IL-33 participates in many diseases with dual, pro-inflammatory or protective roles depending on the cellular and cytokine context. However, the role of IL-33/ST2 axis in carcinogenesis, tumour progression and prognosis is still unclear. Prohibitin (PHB) is a multifunctional protein located in different intracellular sites. It shows overexpression in many cancers suggesting its role in tumourigenesis. Aim: The present work was designed to study the clinicopathological and prognostic significance of IL-33/ST2 axis and prohibitin in breast cancer. Subjects & Methods: The current study was conducted on 45 patients with breast lesions (benign lesions, early and advanced breast cancer) and 15 healthy volunteers. IL-33 and ST2 serum levels were measured by ELISA. Expressions of IL-33 and prohibitin in breast tissue were assessed by immunohistochemistry. Results: Serum levels of IL-33 and immunohistochemical expression of prohibitin were significantly increased in groups with breast lesions compared to the control group (p <0.05). Immunohistochemical expression of IL-33 showed significant differences between malignant tumours and control group (p <0.05), while benign lesions showed higher expression than the control group but the difference was statistically insignificant (p >0.05). In addition, Serum levels of IL-33 as well as immunohistochemical expressions of IL-33 and prohibitin were significantly higher in breast cancer cases compared to those with benign breast lesions (p <0.05), moreover, they showed significant increase with progression of cancer from early "stage I and II" to advanced breast cancer "stage III" (p <0.05). Serum levels of sST2 were significantly higher in breast lesions compared to the control group (p <0.001); however, they were lower in malignant cases than these with benign lesions, but the differences were statistically insignificant (p =0.158). There was a significant positive correlation between the serum level of IL-33 and its immunohistochemical expression in all studied groups (p <0.05), and a significant positive correlation between IL-33 and prohibitin immunohistochemical expression in malignant breast tumours (p <0.05). Conclusion: IL-33/ST2 and prohibitin have vital roles in breast cancer development.  The increased expression of IL-33 and prohibitin with increasing tumour grade and stage indicates that they may be useful prognostic markers for breast cancer.

[Amina El-Sayed, Amany A. Ghazy, Rabie R. Abdelwahed, Eman M. Saied. IL-33/ST2 Axis and Prohibitin in Breast Cancer: Clinicopathological and Prognostic Significance. Cancer Biology 2016;6(4):48-56]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 7. doi:10.7537/marscbj060416.07.

 

Key words: Breast cancer, IL-33/ST2, Prohibitin, Prognosis, IHC

Full Text

7

8

 

Full Text

8

9

 

Full Text

9

10

 

Full Text

10

11

 

Full Text

11

12

 

Full Text

12

13

 

Full Text

13

14

 

Full Text

14

15

 

Full Text

15

16

 

Full Text

16

17

 

Full Text

17

18

 

Full Text

18

19

 

Full Text

19

20

 

Full Text

20

21

 

Full Text

21

22

 

Full Text

22

23

 

Full Text

23

24

 

Full Text

24

25

 

Full Text

25

26

 

Full Text

26

27

 

Full Text

27

28

 

Full Text

28

29

 

Full Text

29

30

 

Full Text

30

31

 

Full Text

31

32

 

Full Text

32

33

 

Full Text

33

34

 

Full Text

34

35

 

Full Text

35

36

 

Full Text

36

37

 

Full Text

37

38

 

Full Text

38

39

 

Full Text

39

40

 

Full Text

40

41

 

Full Text

41

42

 

Full Text

42

43

 

Full Text

43

44

 

Full Text

44

45

 

Full Text

45

46

 

Full Text

46

47

 

Full Text

47

48

 

Full Text

48

49

 

Full Text

49

50

 

Full Text

50

51

 

Full Text

51

52

 

Full Text

52

53

 

Full Text

53

54

 

Full Text

54

55

 

Full Text

55

56

 

Full Text

56

57

 

Full Text

57

58

 

Full Text

58

59

 

Full Text

59

60

 

Full Text

60

61

 

Full Text

61

62

 

Full Text

62

63

 

Full Text

63

64

 

Full Text

64

65

 

Full Text

65

66

 

Full Text

66

67

 

Full Text

67

68

 

Full Text

68

69

 

Full Text

69

70

 

Full Text

70

71

 

Full Text

71

72

 

Full Text

72

73

 

Full Text

73

74

 

Full Text

74

75

 

Full Text

75

76

 

Full Text

76

77

 

Full Text

77

78

 

Full Text

78

79

 

Full Text

79

80

 

Full Text

80

81

 

Full Text

81

82

 

Full Text

82

83

 

Full Text

83

84

 

Full Text

84

85

 

Full Text

85

86

 

Full Text

86

87

 

Full Text

87

88

 

Full Text

88

89

 

Full Text

89

90

 

Full Text

90

91

 

Full Text

91

92

 

Full Text

92

93

 

Full Text

93

94

 

Full Text

94

95

 

Full Text

95

96

 

Full Text

96

97

 

Full Text

97

98

 

Full Text

98

99

 

Full Text

99

100

 

Full Text

100

101

 

Full Text

101

102

 

Full Text

102

103

 

Full Text

103

104

 

Full Text

104

105

 

Full Text

105

106

 

Full Text

106

107

 

Full Text

107

108

 

Full Text

108

109

 

Full Text

109

110

 

Full Text

110

111

 

Full Text

111

112

 

Full Text

112

113

 

Full Text

113

114

 

Full Text

114

115

 

Full Text

115

116

 

Full Text

116

117

 

Full Text

117

118

 

Full Text

118

119

 

Full Text

119

120

 

Full Text

120

121

 

Full Text

121

122

 

Full Text

122

123

 

Full Text

123

124

 

Full Text

124

125

 

Full Text

125

126

 

Full Text

126

127

 

Full Text

127

128

 

Full Text

128

129

 

Full Text

129

130

 

Full Text

130

131

 

Full Text

131

132

 

Full Text

132

133

 

Full Text

133

134

 

Full Text

134

135

 

Full Text

135

136

 

Full Text

136

137

 

Full Text

137

138

 

Full Text

138

139

 

Full Text

139

140

 

Full Text

140

141

 

Full Text

141

142

 

Full Text

142

143

 

Full Text

143

144

 

Full Text

144

145

 

Full Text

145

146

 

Full Text

146

147

 

Full Text

147

148

 

Full Text

148

149

 

Full Text

149

150

 

Full Text

150

151

 

Full Text

151

152

 

Full Text

152

153

 

Full Text

153

154

 

Full Text

154

155

 

Full Text

155

156

 

Full Text

156

157

 

Full Text

157

158

 

Full Text

158

159

 

Full Text

159

160

 

Full Text

160

161

 

Full Text

161

162

 

Full Text

162

163

 

Full Text

163

164

 

Full Text

164

165

 

Full Text

165

166

 

Full Text

166

167

 

Full Text

167

168

 

Full Text

168

169

 

Full Text

169

170

 

Full Text

170

171

 

Full Text

171

172

 

Full Text

172

173

 

Full Text

173

174

 

Full Text

174

175

 

Full Text

175

176

 

Full Text

176

177

 

Full Text

177

178

 

Full Text

178

179

 

Full Text

179

180

 

Full Text

180

181

 

Full Text

181

182

 

Full Text

182

183

 

Full Text

183

184

 

Full Text

184

185

 

Full Text

185

186

 

Full Text

186

187

 

Full Text

187

188

 

Full Text

188

189

 

Full Text

189

190

 

Full Text

190

191

 

Full Text

191

192

 

Full Text

192

193

 

Full Text

193

194

 

Full Text

194

195

 

Full Text

195

196

 

Full Text

196

197

 

Full Text

197

198

 

Full Text

198

199

 

Full Text

199

200

 

Full Text

200

201

 

Full Text

201

202

 

Full Text

202

203

 

Full Text

203

204

 

Full Text

204

205

 

Full Text

205

206

 

Full Text

206

207

 

Full Text

207

208

 

Full Text

208

209

 

Full Text

209

210

 

Full Text

210

211

 

Full Text

211

212

 

Full Text

212

213

 

Full Text

213

214

 

Full Text

214

215

 

Full Text

215

216

 

Full Text

216

217

 

Full Text

217

218

 

Full Text

218

219

 

Full Text

219

220

 

Full Text

220

221

 

Full Text

221

222

 

Full Text

222

223

 

Full Text

223

224

 

Full Text

224

225

 

Full Text

225

226

 

Full Text

226

227

 

Full Text

227

228

 

Full Text

228

229

 

Full Text

229

230

 

Full Text

230

231

 

Full Text

231

232

 

Full Text

232

233

 

Full Text

233

234

 

Full Text

234

235

 

Full Text

235

236

 

Full Text

236

237

 

Full Text

237

238

 

Full Text

238

239

 

Full Text

239

240

 

Full Text

240

241

 

Full Text

241

242

 

Full Text

242

243

 

Full Text

243

244

 

Full Text

244

245

 

Full Text

245

246

 

Full Text

246

247

 

Full Text

247

248

 

Full Text

248

249

 

Full Text

249

250

 

Full Text

250

251

 

Full Text

251

252

 

Full Text

252

253

 

Full Text

253

254

 

Full Text

254

255

 

Full Text

255

256

 

Full Text

256

257

 

Full Text

257

258

 

Full Text

258

259

 

Full Text

259

260

 

Full Text

260

261

 

Full Text

261

262

 

Full Text

262

263

 

Full Text

263

264

 

Full Text

264

265

 

Full Text

265

266

 

Full Text

266

267

 

Full Text

267

268

 

Full Text

268

269

 

Full Text

269

270

 

Full Text

270

271

 

Full Text

271

272

 

Full Text

272

273

 

Full Text

273

274

 

Full Text

274

275

 

Full Text

275

276

 

Full Text

276

277

 

Full Text

277

278

 

Full Text

278

279

 

Full Text

279

280

 

Full Text

280

281

 

Full Text

281

282

 

Full Text

282

283

 

Full Text

283

284

 

Full Text

284

285

 

Full Text

285

286

 

Full Text

286

287

 

Full Text

287

288

 

Full Text

288

289

 

Full Text

289

290

 

Full Text

290

291

 

Full Text

291

292

 

Full Text

292

293

 

Full Text

293

294

 

Full Text

294

295

 

Full Text

295

296

 

Full Text

296

297

 

Full Text

297

298

 

Full Text

298

299

 

Full Text

299

300

 

Full Text

300

301

 

Full Text

301

302

 

Full Text

302

303

 

Full Text

303

304

 

Full Text

304

305

 

Full Text

305

306

 

Full Text

306

307

 

Full Text

307

308

 

Full Text

308

309

 

Full Text

309

310

 

Full Text

310

311

 

Full Text

311

312

 

Full Text

312

313

 

Full Text

313

314

 

Full Text

314

315

 

Full Text

315

316

 

Full Text

316

317

 

Full Text

317

318

 

Full Text

318

319

 

Full Text

319

320

 

Full Text

320

321

 

Full Text

321

322

 

Full Text

322

323

 

Full Text

323

324

 

Full Text

324

325

 

Full Text

325

326

 

Full Text

326

327

 

Full Text

327

328

 

Full Text

328

329

 

Full Text

329

330

 

Full Text

330

331

 

Full Text

331

332

 

Full Text

332

333

 

Full Text

333

334

 

Full Text

334

335

 

Full Text

335

336

 

Full Text

336

337

 

Full Text

337

338

 

Full Text

338

339

 

Full Text

339

340

 

Full Text

340

341

 

Full Text

341

342

 

Full Text

342

343

 

Full Text

343

344

 

Full Text

344

345

 

Full Text

345

346

 

Full Text

346

347

 

Full Text

347

348

 

Full Text

348

349

 

Full Text

349

350

 

Full Text

350

351

 

Full Text

351

352

 

Full Text

352

353

 

Full Text

353

354

 

Full Text

354

355

 

Full Text

355

356

 

Full Text

356

357

 

Full Text

357

358

 

Full Text

358

359

 

Full Text

359

360

 

Full Text

360

361

 

Full Text

361

362

 

Full Text

362

363

 

Full Text

363

364

 

Full Text

364

365

 

Full Text

365

366

 

Full Text

366

367

 

Full Text

367

368

 

Full Text

368

369

 

Full Text

369

370

 

Full Text

370

371

 

Full Text

371

372

 

Full Text

372

373

 

Full Text

373

374

 

Full Text

374

375

 

Full Text

375

376

 

Full Text

376

377

 

Full Text

377

378

 

Full Text

378

379

 

Full Text

379

380

 

Full Text

380

381

 

Full Text

381

382

 

Full Text

382

383

 

Full Text

383

384

 

Full Text

384

385

 

Full Text

385

386

 

Full Text

386

387

 

Full Text

387

388

 

Full Text

388

389

 

Full Text

389

390

 

Full Text

390

391

 

Full Text

391

392

 

Full Text

392

393

 

Full Text

393

394

 

Full Text

394

395

 

Full Text

395

396

 

Full Text

396

397

 

Full Text

397

398

 

Full Text

398

399

 

Full Text

399

400

 

Full Text

400

401

 

Full Text

401

402

 

Full Text

402

403

 

Full Text

403

404

 

Full Text

404

405

 

Full Text

405

406

 

Full Text

406

407

 

Full Text

407

408

 

Full Text

408

409

 

Full Text

409

410

 

Full Text

410

411

 

Full Text

411

412

 

Full Text

412

413

 

Full Text

413

414

 

Full Text

414

415

 

Full Text

415

416

 

Full Text

416

417

 

Full Text

417

418

 

Full Text

418

419

 

Full Text

419

420

 

Full Text

420

421

 

Full Text

421

422

 

Full Text

422

423

 

Full Text

423

424

 

Full Text

424

425

 

Full Text

425

426

 

Full Text

426

427

 

Full Text

427

428

 

Full Text

428

429

 

Full Text

429

430

 

Full Text

430

431

 

Full Text

431

432

 

Full Text

432

433

 

Full Text

433

434

 

Full Text

434

435

 

Full Text

435

436

 

Full Text

436

437

 

Full Text

437

438

 

Full Text

438

439

 

Full Text

439

440

 

Full Text

440

441

 

Full Text

441

442

 

Full Text

442

443

 

Full Text

443

444

 

Full Text

444

445

 

Full Text

445

446

 

Full Text

446

447

 

Full Text

447

448

 

Full Text

448

449

 

Full Text

449

450

 

Full Text

450

451

 

Full Text

451

452

 

Full Text

452

453

 

Full Text

453

454

 

Full Text

454

455

 

Full Text

455

456

 

Full Text

456

457

 

Full Text

457

458

 

Full Text

458

459

 

Full Text

459

460

 

Full Text

460

461

 

Full Text

461

462

 

Full Text

462

463

 

Full Text

463

464

 

Full Text

464

465

 

Full Text

465

466

 

Full Text

466

467

 

Full Text

467

468

 

Full Text

468

469

 

Full Text

469

470

 

Full Text

470

471

 

Full Text

471

472

 

Full Text

472

473

 

Full Text

473

474

 

Full Text

474

475

 

Full Text

475

476

 

Full Text

476

477

 

Full Text

477

478

 

Full Text

478

479

 

Full Text

479

480

 

Full Text

480

481

 

Full Text

481

482

 

Full Text

482

483

 

Full Text

483

484

 

Full Text

484

485

 

Full Text

485

486

 

Full Text

486

487

 

Full Text

487

488

 

Full Text

488

489

 

Full Text

489

490

 

Full Text

490

491

 

Full Text

491

492

 

Full Text

492

493

 

Full Text

493

494

 

Full Text

494

495

 

Full Text

495

496

 

Full Text

496

497

 

Full Text

497

498

 

Full Text

498

499

 

Full Text

499

500

 

Full Text

500

501

 

Full Text

501

502

 

Full Text

502

503

 

Full Text

503

504

 

Full Text

504

505

 

Full Text

505

506

 

Full Text

506

507

 

Full Text

507

508

 

Full Text

508

509

 

Full Text

509

510

 

Full Text

510

511

 

Full Text

511

512

 

Full Text

512

513

 

Full Text

513

514

 

Full Text

514

515

 

Full Text

515

516

 

Full Text

516

517

 

Full Text

517

518

 

Full Text

518

519

 

Full Text

519

520

 

Full Text

520

521

 

Full Text

521

522

 

Full Text

522

523

 

Full Text

523

524

 

Full Text

524

525

 

Full Text

525

526

 

Full Text

526

527

 

Full Text

527

528

 

Full Text

528

529

 

Full Text

529

530

 

Full Text

530

531

 

Full Text

531

532

 

Full Text

532

533

 

Full Text

533

534

 

Full Text

534

535

 

Full Text

535

536

 

Full Text

536

537

 

Full Text

537

538

 

Full Text

538

539

 

Full Text

539

540

 

Full Text

540

541

 

Full Text

541

542

 

Full Text

542

543

 

Full Text

543

544

 

Full Text

544

545

 

Full Text

545

546

 

Full Text

546

547

 

Full Text

547

548

 

Full Text

548

549

 

Full Text

549

550

 

Full Text

550

551

 

Full Text

551

552

 

Full Text

552

553

 

Full Text

553

554

 

Full Text

554

555

 

Full Text

555

556

 

Full Text

556

557

 

Full Text

557

558

 

Full Text

558

559

 

Full Text

559

560

 

Full Text

560

561

 

Full Text

561

562

 

Full Text

562

563

 

Full Text

563

564

 

Full Text

564

565

 

Full Text

565

566

 

Full Text

566

567

 

Full Text

567

568

 

Full Text

568

569

 

Full Text

569

570

 

Full Text

570

571

 

Full Text

571

572

 

Full Text

572

573

 

Full Text

573

574

 

Full Text

574

575

 

Full Text

575

576

 

Full Text

576

577

 

Full Text

577

578

 

Full Text

578

579

 

Full Text

579

580

 

Full Text

580

581

 

Full Text

581

582

 

Full Text

582

583

 

Full Text

583

584

 

Full Text

584

585

 

Full Text

585

586

 

Full Text

586

587

 

Full Text

587

588

 

Full Text

588

589

 

Full Text

589

590

 

Full Text

590

591

 

Full Text

591

592

 

Full Text

592

593

 

Full Text

593

594

 

Full Text

594

595

 

Full Text

595

596

 

Full Text

596

597

 

Full Text

597

598

 

Full Text

598

599

 

Full Text

599

600

 

Full Text

600

601

 

Full Text

601

602

 

Full Text

602

603

 

Full Text

603

604

 

Full Text

604

605

 

Full Text

605

606

 

Full Text

606

607

 

Full Text

607

608

 

Full Text

608

609

 

Full Text

609

610

 

Full Text

610

611

 

Full Text

611

612

 

Full Text

612

613

 

Full Text

613

614

 

Full Text

614

615

 

Full Text

615

616

 

Full Text

616

617

 

Full Text

617

618

 

Full Text

618

619

 

Full Text

619

620

 

Full Text

620

621

 

Full Text

621

622

 

Full Text

622

623

 

Full Text

623

624

 

Full Text

624

625

 

Full Text

625

626

 

Full Text

626

627

 

Full Text

627

628

 

Full Text

628

629

 

Full Text

629

630

 

Full Text

630

631

 

Full Text

631

632

 

Full Text

632

633

 

Full Text

633

634

 

Full Text

634

635

 

Full Text

635

636

 

Full Text

636

637

 

Full Text

637

638

 

Full Text

638

639

 

Full Text

639

640

 

Full Text

640

641

 

Full Text

641

642

 

Full Text

642

643

 

Full Text

643

644

 

Full Text

644

645

 

Full Text

645

646

 

Full Text

646

647

 

Full Text

647

648

 

Full Text

648

649

 

Full Text

649

650

 

Full Text

650

651

 

Full Text

651

652

 

Full Text

652

653

 

Full Text

653

654

 

Full Text

654

655

 

Full Text

655

656

 

Full Text

656

657

 

Full Text

657

658

 

Full Text

658

659

 

Full Text

659

660

 

Full Text

660

661

 

Full Text

661

662

 

Full Text

662

663

 

Full Text

663

664

 

Full Text

664

665

 

Full Text

665

666

 

Full Text

666

667

 

Full Text

667

668

 

Full Text

668

669

 

Full Text

669

670

 

Full Text

670

671

 

Full Text

671

672

 

Full Text

672

673

 

Full Text

673

674

 

Full Text

674

675

 

Full Text

675

676

 

Full Text

676

677

 

Full Text

677

678

 

Full Text

678

679

 

Full Text

679

680

 

Full Text

680

681

 

Full Text

681

682

 

Full Text

682

683

 

Full Text

683

684

 

Full Text

684

685

 

Full Text

685

686

 

Full Text

686

687

 

Full Text

687

688

 

Full Text

688

689

 

Full Text

689

690

 

Full Text

690

691

 

Full Text

691

692

 

Full Text

692

693

 

Full Text

693

694

 

Full Text

694

695

 

Full Text

695

696

 

Full Text

696

697

 

Full Text

697

698

 

Full Text

698

699

 

Full Text

699

700

 

Full Text

700

701

 

Full Text

701

702

 

Full Text

702

703

 

Full Text

703

704

 

Full Text

704

705

 

Full Text

705

706

 

Full Text

706

707

 

Full Text

707

708

 

Full Text

708

709

 

Full Text

709

710

 

Full Text

710

The manuscripts in this issue were presented as online first for peer-review starting from October 18, 2016

 All comments are welcome: editor@sciencepub.net

For back issues of the Researcher, click here.

Emails: editor@sciencepub.net 

Marsland Press: http://www.sciencepub.net

 

For back issues of the Cancer Biology: click here.

 

 

Marsland Press: http://www.sciencepub.net

 

2016 Marsland Press

 

 

 

 

Web counter since January 1, 2010

daily hits
Quality Inns